

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

### **翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

## **VOLUNTARY ANNOUNCEMENT**

### **CLINICAL TRIAL NOTICE OF “HS-20105”**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “HS-20105”, a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited\* (上海翰森生物醫藥科技有限公司) and Changzhou Hansoh Pharmaceutical Company Limited\* (常州恒邦藥業有限公司), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People’s Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research.

#### **ABOUT “HS-20105”**

HS-20105 is an antibody-drug conjugate formed by coupling humanized anti-Trop-2 monoclonal antibody of IgG1 subtype with cytotoxic payload (DNA topoisomerase I inhibitor) by the cleavable linker.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, September 25, 2023

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* *For identification purposes only*